Rezolute (RZLT) Gains from Investment Securities (2017 - 2026)

Rezolute recorded quarterly Gains from Investment Securities of $2.2 million in Q1 2026, down 69.04% quarter-over-quarter from $7.1 million in Q4 2025, and down 82.58% year-over-year from $12.6 million in Q1 2025.

Rezolute's Gains from Investment Securities history runs 10 years deep, the most recent figure standing at $2.2 million for Q1 2026.

  • In Q1 2026, Gains from Investment Securities fell 82.58% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (down 82.58% YoY), while the FY2025 annual figure was $13.0 million, up 393.2% from the prior year.
  • Gains from Investment Securities came in at $2.2 million for Q1 2026 at Rezolute, down from $7.1 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $12.6 million in Q1 2025 to a low of $2000.0 in Q3 2024.
  • A 5-year average of $5.0 million and a median of $2.5 million in 2024 frame the typical range for Gains from Investment Securities.
  • Across the five-year window, Gains from Investment Securities tumbled 99.98% in 2024 and jumped 49153.8% in 2025, its largest moves.
  • Rezolute's Gains from Investment Securities stood at $8.5 million in 2022, then sank by 76.15% to $2.0 million in 2023, then surged by 441.05% to $11.0 million in 2024, then plunged by 35.2% to $7.1 million in 2025, then plunged by 69.04% to $2.2 million in 2026.
  • According to Business Quant data, Gains from Investment Securities over the past three periods registered $2.2 million, $7.1 million, and $985076.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Rezolute 374.41 Mn 374.41 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 2.20 Mn
Mar 31, 2026 2.20 Mn
Dec 31, 2025 7.11 Mn
Dec 31, 2025 7.11 Mn
Sep 30, 2025 985,076.00
Sep 30, 2025 985,076.00
Jun 30, 2025 400,000.00
Jun 30, 2025 400,000.00
Mar 31, 2025 12.63 Mn
Mar 31, 2025 12.63 Mn
Dec 31, 2024 10.97 Mn
Dec 31, 2024 10.97 Mn
Sep 30, 2024 2,000.00
Sep 30, 2024 2,000.00
Mar 31, 2024 2.48 Mn
Mar 31, 2024 2.48 Mn
Dec 31, 2023 2.03 Mn
Dec 31, 2023 2.03 Mn
Sep 30, 2023 9.11 Mn
Sep 30, 2023 9.11 Mn
Mar 31, 2023 668,000.00
Mar 31, 2023 668,000.00
Dec 31, 2022 8.50 Mn
Dec 31, 2022 8.50 Mn
Sep 30, 2022 8.48 Mn
Sep 30, 2022 8.48 Mn
Jun 30, 2022 8.51 Mn
Jun 30, 2022 8.51 Mn
Mar 31, 2022 1.59 Mn
Mar 31, 2022 1.59 Mn
Dec 31, 2021 1.31 Mn
Dec 31, 2021 1.31 Mn
Sep 30, 2021 1.33 Mn
Sep 30, 2021 1.33 Mn
Mar 31, 2021 77,000.00
Mar 31, 2021 77,000.00
Dec 31, 2020 43,000.00
Dec 31, 2020 43,000.00
Sep 30, 2020 3,000.00
Sep 30, 2020 3,000.00
Mar 31, 2020 48.16 Mn
Mar 31, 2020 48.16 Mn
Dec 31, 2019 35.95 Mn
Dec 31, 2019 35.95 Mn
Sep 30, 2019 5.61 Mn
Sep 30, 2019 5.61 Mn
Jun 30, 2019 24,000.00
Jun 30, 2019 24,000.00
Mar 31, 2019 11,000.00
Mar 31, 2019 11,000.00
Dec 31, 2018 -46,000.00
Dec 31, 2018 -46,000.00
Sep 30, 2018 5,000.00
Sep 30, 2018 5,000.00
Jun 30, 2018 -663,000.00
Jun 30, 2018 -663,000.00
Mar 31, 2018 -535,303.00
Mar 31, 2018 -535,303.00
Jun 30, 2017 21,291.00
Jun 30, 2017 21,291.00